Survival and diagnostic age of 175 Taiwanese patients with mucopolysaccharidoses (1985-2019).
Early diagnosis
Mucopolysaccharidosis
Newborn screening
Survival
Taiwan
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
07 11 2020
07 11 2020
Historique:
received:
05
06
2020
accepted:
26
10
2020
entrez:
8
11
2020
pubmed:
9
11
2020
medline:
22
6
2021
Statut:
epublish
Résumé
Mucopolysaccharidoses (MPSs) are a group of inherited metabolic diseases, which are characterized by the accumulation of glycosaminoglycans, and eventually lead to the progressive damage of various tissues and organs. An epidemiological study of MPS in Taiwan was performed using multiple sources. The survival and diagnostic age for different types of MPS between 1985 and 2019 were evaluated. Between 1985 and 2019, there were 175 patients diagnosed with MPS disorders in the Taiwanese population, with a median diagnostic age of 3.9 years. There were 21 (12%), 78 (45%), 33 (19%), 32 (18%) and 11 (6%) patients diagnosed with MPS I, II, III, IV and VI, respectively, with median diagnostic ages of 1.5, 3.8, 4.7, 4.5 and 3.7 years, respectively. Diagnosis of MPS patients was significantly earlier in recent decades (p < 0.01). Pilot newborn screening programs for MPS I, II, VI, IVA, and IIIB were progressively introduced in Taiwan from 2016, and 48% (16/33) of MPS patients diagnosed between 2016 and 2019 were diagnosed by one of these screening programs, with a median diagnostic age at 0.2 years. For patients born between 2016 and 2019, up to 94% (16/17) were diagnosed with MPS via the newborn screening programs. At the time of this study, 81 patients had passed away with a median age at death of 15.6 years. Age at diagnosis was positively correlated with life expectancy (p < 0.01). Life expectancy also significantly increased between 1985 and 2019, however this increase was gradual (p < 0.01). The life expectancy of Taiwanese patients with MPS has improved in recent decades and patients are being diagnosed earlier. Because of the progressive nature of the disease, early diagnosis by newborn screening programs and timely implementation of early therapeutic interventions may lead to better clinical outcomes.
Sections du résumé
BACKGROUND
Mucopolysaccharidoses (MPSs) are a group of inherited metabolic diseases, which are characterized by the accumulation of glycosaminoglycans, and eventually lead to the progressive damage of various tissues and organs.
METHODS
An epidemiological study of MPS in Taiwan was performed using multiple sources. The survival and diagnostic age for different types of MPS between 1985 and 2019 were evaluated.
RESULTS
Between 1985 and 2019, there were 175 patients diagnosed with MPS disorders in the Taiwanese population, with a median diagnostic age of 3.9 years. There were 21 (12%), 78 (45%), 33 (19%), 32 (18%) and 11 (6%) patients diagnosed with MPS I, II, III, IV and VI, respectively, with median diagnostic ages of 1.5, 3.8, 4.7, 4.5 and 3.7 years, respectively. Diagnosis of MPS patients was significantly earlier in recent decades (p < 0.01). Pilot newborn screening programs for MPS I, II, VI, IVA, and IIIB were progressively introduced in Taiwan from 2016, and 48% (16/33) of MPS patients diagnosed between 2016 and 2019 were diagnosed by one of these screening programs, with a median diagnostic age at 0.2 years. For patients born between 2016 and 2019, up to 94% (16/17) were diagnosed with MPS via the newborn screening programs. At the time of this study, 81 patients had passed away with a median age at death of 15.6 years. Age at diagnosis was positively correlated with life expectancy (p < 0.01). Life expectancy also significantly increased between 1985 and 2019, however this increase was gradual (p < 0.01).
CONCLUSIONS
The life expectancy of Taiwanese patients with MPS has improved in recent decades and patients are being diagnosed earlier. Because of the progressive nature of the disease, early diagnosis by newborn screening programs and timely implementation of early therapeutic interventions may lead to better clinical outcomes.
Identifiants
pubmed: 33160388
doi: 10.1186/s13023-020-01598-z
pii: 10.1186/s13023-020-01598-z
pmc: PMC7648385
doi:
Substances chimiques
Glycosaminoglycans
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
314Références
Sci Rep. 2019 Jul 24;9(1):10755
pubmed: 31341247
J Pediatr. 2004 May;144(5):581-8
pubmed: 15126990
Orphanet J Rare Dis. 2014 Sep 02;9:135
pubmed: 25178307
Pediatr Neonatol. 2019 Oct;60(5):577-578
pubmed: 31196723
Biol Blood Marrow Transplant. 2015 Jun;21(6):1106-9
pubmed: 25708213
Mol Genet Metab. 2016 Sep;119(1-2):131-43
pubmed: 27380995
Orphanet J Rare Dis. 2013 Sep 22;8:147
pubmed: 24053568
Orphanet J Rare Dis. 2017 Oct 23;12(1):168
pubmed: 29061114
JIMD Rep. 2015;15:59-66
pubmed: 24718838
Mol Genet Metab. 2016 Apr;117(4):438-46
pubmed: 26846156
Orphanet J Rare Dis. 2015 Oct 07;10:131
pubmed: 26446585
Mol Genet Metab Rep. 2016 Apr 18;7:63-9
pubmed: 27134829
Mol Genet Genomic Med. 2018 Nov;6(6):982-992
pubmed: 30296009
J Clin Lab Anal. 2002;16(5):253-8
pubmed: 12357455
Intractable Rare Dis Res. 2014 Aug;3(3):79-86
pubmed: 25364648
Pediatr Neonatol. 2019 Jun;60(3):342-343
pubmed: 30241882
Orphanet J Rare Dis. 2018 May 25;13(1):84
pubmed: 29801497
Diagnostics (Basel). 2019 Oct 05;9(4):
pubmed: 31590383
Eur J Pediatr. 2008 Mar;167(3):267-77
pubmed: 18038146
Rheumatology (Oxford). 2011 Dec;50 Suppl 5:v4-12
pubmed: 22210669
J Pediatr. 2004 May;144(5 Suppl):S27-34
pubmed: 15126981
Mol Genet Metab. 2016 Nov;119(3):239-248
pubmed: 27590925
Am J Med Genet A. 2014 Aug;164A(8):1953-64
pubmed: 24764221
Genet Med. 2006 Aug;8(8):465-73
pubmed: 16912578
Mol Genet Metab Rep. 2017 Sep 14;13:69-75
pubmed: 28983456
Orphanet J Rare Dis. 2020 Feb 3;15(1):38
pubmed: 32014045
Diagnostics (Basel). 2019 Oct 14;9(4):
pubmed: 31615002
Hum Genet. 1999 Jul-Aug;105(1-2):151-6
pubmed: 10480370
Drugs. 2019 Jul;79(10):1103-1134
pubmed: 31209777
Mol Genet Metab. 2018 Apr;123(4):488-494
pubmed: 29478819
J Inherit Metab Dis. 2009 Aug;32(4):534-43
pubmed: 19597960
Am J Med Genet A. 2009 May;149A(5):960-4
pubmed: 19396827
Mol Genet Metab. 2017 Jul;121(3):227-240
pubmed: 28595941
J Pediatr. 2019 Feb;205:176-182
pubmed: 30409495
Orphanet J Rare Dis. 2016 Jun 27;11(1):85
pubmed: 27349225
Mol Genet Metab. 2008 Aug;94(4):469-75
pubmed: 18502162
Eur J Pediatr. 2012 Jun;171(6):911-9
pubmed: 22234477
Pediatr Pulmonol. 2014 Mar;49(3):277-84
pubmed: 23401495
Am J Med Genet A. 2018 Sep;176(9):1799-1809
pubmed: 30070758
Mol Genet Genomic Med. 2019 Aug;7(8):e790
pubmed: 31215158
Orphanet J Rare Dis. 2014 Feb 10;9:21
pubmed: 24513086
Am J Med Genet A. 2012 Jan;158A(1):90-6
pubmed: 22105882
J Inherit Metab Dis. 2007 Apr;30(2):165-74
pubmed: 17347914